Stocks · News reference
MapLight Therapeutics Stock Falls Despite Schizophrenia Drug Meeting Main Trial Goal
MapLight says Phase 2 schizophrenia data showed strong twice-daily efficacy while the once-daily dose missed the primary endpoint.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — MapLight Therapeutics, Inc. (MPLT)
Filed: 2026-08-13 AccNo: 0001193125-26-349490 Size: 4 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.02: Results of Operations and Financial Condition Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
MapLight Therapeutics Q2 EPS $(1.32) Beats $(1.35) Estimate
MapLight Therapeutics Enters Securities Purchase Agreement For $150M Private Placement Financing
MapLight Therapeutics, Inc. (NASDAQ:MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders, announced today that it has